pretickt

AMGN financials

Amgen Inc. · end-of-day data as of Oct 16, 2026

Amgen Inc.
AMGN · $234B
$432.49+15.7%last 60 sessions · close Oct 16, 2026
$283.30$444.1252 weeks
Hold · 34 analystsPT $400.03 -7.5%
  • P/E vs own+17.1%
  • P/E vs sector-4.5%
  • Target upside-7.5%
  • Off 52w high-2.6%
  • Insiders-$2.48M
  • FCF yield+4.4%
  • Earnings in18d
  • Trendbullish
  • Sector▲ +16.0%
  • RSI63
  • MA20×50↑ in ~1d
  • Volume0.9x
  • Support-10.5%
  • Resistance+2.7%

AMGN reported revenue of $10.05B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 9.7% from a year earlier. It posted diluted EPS of $4.37, free cash flow of $3.49B and a net margin of 23.6%.

Valuation

  • P/E26.9x
  • P/E vs own+17.1%
  • P/E vs sector-4.5%
  • FCF yield+4.4%
  • Market cap$234B

Quarterly results

Q2 FY2026: Revenue +9.7% year over year, free cash flow 34.7% of revenue, operating margin 35.0%.

RevenueFree cash flow
Q3 FY2023Q4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026
Q2 FY2026Jun 30, 2026$10.05B4.37$3.49B72.0%35.0%23.6%
Q1 FY2026Mar 31, 2026$8.62B3.34$1.48B68.2%30.9%21.1%
Q4 FY2025Dec 31, 2025$9.9B2.45$961M81.9%39.8%13.5%
Q3 FY2025Sep 30, 2025$9.56B5.93$4.25B67.8%26.4%33.7%
Q2 FY2025Jun 30, 2025$9.17B2.65$1.91B67.2%28.8%15.6%
Q1 FY2025Mar 31, 2025$8.15B3.20$980M63.6%14.5%21.2%
Q4 FY2024Dec 31, 2024$9.09B1.16$4.4B65.7%25.4%6.9%
Q3 FY2024Sep 30, 2024$8.5B5.22$3.31B61.1%24.1%33.3%
Q2 FY2024Jun 30, 2024$8.39B1.38$2.22B61.4%22.8%8.9%
Q1 FY2024Mar 31, 2024$7.45B-0.21$459M57.0%13.3%-1.5%
Q4 FY2023Dec 31, 2023$8.2B1.42$289M62.0%15.5%9.4%
Q3 FY2023Sep 30, 2023$6.9B3.22$2.51B73.8%29.3%25.1%